Johnson & Johnson news in 2026: 31 dated events
The latest Johnson & Johnson event on this page is dated Nov 16, 2026. boursorama.com reported: J&J to acquire eye disease-focused biotech firm Ollin Biosciences for up to.
Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API
What changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.- Dated events
- 31
- Last 90 days
- 30
- Latest
- Nov 16, 2026
Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated
News · latest 10
Latest Johnson & Johnson news
Showing 10 of 31 dated events. The Signal API returns all of them.
Get them with one API call- J&J to acquire eye disease-focused biotech firm Ollin Biosciences for up toWith Blackstone Life Sciences
- J&J Secures $750 Million in Blackstone R&D Funding, Pending Ollin ClosingJohnson & Johnson secured $750 million in R&D funding from Blackstone Life Sciences for Phase 3 development of OLN324, contingent on closing its Ollin acquisition.
- Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.3 BillionJohnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront and up to approximately $1.1 billion in milestone payments.
- Johnson & Johnson Stock: New Investments in Cancer and PsychiatryWith Francis Medical
- Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerJohnson & Johnson is developing an investigational dual-antigen immunotherapy combination of pasritamig and JNJ-9401 for the treatment of advanced prostate cancer, with the regimen entering Phase 3 development.
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily...Johnson & Johnson announced positive Phase 3 results for its investigational targeted oral peptide ICOTYDE (icotrokinra) in treating biologic-naive adults with active psoriatic arthritis.
- RYBREVANT®▼ (amivantamab) subcutaneous demonstrates a 77 percent objective response rate in first-line treatment for patients with certain advanced forms of head and neck cancerJohnson & Johnson released results from the Phase 1b/2 OrigAMI-4 study and expanded the clinical development of subcutaneous RYBREVANT (amivantamab) for head and neck cancer.
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerJohnson & Johnson is developing subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) in ongoing Phase 1b/2 and Phase 3 clinical studies for advanced head and neck cancer.
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerJohnson & Johnson announced Phase 3 PROTEUS substudy results evaluating the investigational use of ERLEADA (apalutamide) plus androgen deprivation therapy before and after surgery in high-risk prostate cancer.
Showing 10 of 31 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Johnson & Johnson with the Signal API
One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about Johnson & Johnson news
What is the latest news on Johnson & Johnson?
What is going on with Johnson & Johnson?
Is Johnson & Johnson laying off employees?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .